en · de · es · fr · pt
compound-index.peptides1126.com › Topic › Identity And Chemical Background — Common Mistakes

Identity And Chemical Background — Common Mistakes

By Editorial Desk · published 2026-05-26 · last reviewed 2026-06-24 · Topic

salt form comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-06-24. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Chemical Background

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Handling, Storage and Analytical Control

Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.

Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.

Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Free base; salt forms differ
Molecular weightApproximately 1024 g/molCalculated for the free base
AppearanceWhite to off-white powderTypically supplied as a lyophilised solid
SolubilitySoluble in water and polar solventsPoorly soluble in non-polar solvents
Typical storage-20 degrees Celsius, dry, protected from lightRefers to the solid form

Chemical Background and Receptor Activity

Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.

The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.

Related pages on this site

Analytical Methods And Storage Stability

Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.

Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.

Further detail

=== Commercialization === Elbasvir/grazoprevir was FDA approved in the United States, and has been approved for use in the European Union, Canada, Japan, Australia, Saudi Arabia, Israel, and Switzerland. Zepatier is one of a few non-interferon therapies that are market-available. Competing treatments include Gilead's Harvoni (sofosbuvir and ledipasvir) and AbbVie's Viekira Pak (ombitasvir, paritaprevir, and ritonavir). Sale projections for Zepatier are $636 million in 2016 and rising to $1.5 billion by 2020. With Merck's release of Zepatier early in 2016, they saw large bumps in share prices in quarters 1 and 2, but are expected to drop down a bit. Zepatier does not have as strong a market hold as other competitive HCV treatments.

== Early life and education == Scrutton was born in Batley, West Riding of Yorkshire and was brought up in Cleckheaton where he went to Whitcliffe Mount School. Scrutton graduated from King's College London with a first class Bachelor of Science degree in Biochemistry in 1985. He was a Benefactors' Scholar at St John's College, Cambridge where he completed his doctoral research (PhD) in 1988 supervised by Richard Perham. He was a Research Fellow of St John's College, Cambridge (1989–92) and a Fellow / Director of Studies at Churchill College, Cambridge (1992–95). He was awarded a Doctor of Science (ScD) degree in 2003 by the University of Cambridge.

Reticular formation, a region in the brainstem that is involved in multiple tasks Reticular activating system, a set of connected nuclei in the brains of vertebrates Reticular cell, a type of fibroblast that produces reticular fibers Reticular connective tissue, a type of connective tissue that has a network of reticular fibers Reticular fiber, a type of fiber in connective tissue that is composed of type III collagen Reticular dermis, the lower layer of the dermis composed of dense irregular connective tissue Reticular dysgenesis, a rare genetic disorder of the bone marrow Reticular erythematous mucinosis, a skin condition that tends to affect women in the third and fourth decades of life Reticular layer, a layer in the adrenal cortex that produces androgens Reticular pigmented anomaly of the flexures, a fibrous anomaly of the flexures or bending parts of the axillae, neck and inframammary/sternal areas

Troponin C binds to calcium ions (Ca2+) to produce a conformational change in TnI Troponin T binds to tropomyosin, interlocking them to form a troponin-tropomyosin complex with thin filaments Troponin I binds to actin in thin myofilaments to hold the actin-tropomyosin complex in place. It inhibits the ATPase activise of actomyosin. Inside the cardiac troponin complex, the strongest interaction between molecules is the cTnI–TnC binary complex, especially in the presence of Ca2+ (KA = 1.5 × 10−8 M−1). TnC, forming a complex with cTnI, changes the conformation of cTnI molecule and shields part of its surface. According to the latest data cTnI is released in the blood stream of the patient in the form of binary complex with TnC or ternary complex with cTnT and TnC. cTnI-TnC complex formation plays an important positive role in improving the stability of cTnI molecule. cTnI, which is extremely unstable in its free form, demonstrates significantly better stability in complex with TnC or in ternary cTnI-cTnT-TnC complex. It has been demonstrated that stability of cTnI in native complex is significantly better than stability of the purified form of the protein or the stability of cTnI in artificial troponin complexes combined from purified proteins.

Sources: en.wikipedia.org

Supporting material

Arthrogryposis multiplex due to muscular dystrophy. Arthrogryposis ectodermal dysplasia other anomalies, also known as Cote Adamopoulos Pantelakis syndrome, Trichooculodermovertebral syndrome, TODV syndrome and Alves syndrome. Arthrogryposis epileptic seizures migrational brain disorder. Arthrogryposis IUGR thoracic dystrophy, also known as Van Bervliet syndrome. Arthrogryposis-like disorder, also known as Kuskokwim disease. Arthrogryposis-like hand anomaly and sensorineural deafness. Arthrogryposis multiplex congenita CNS calcification. Arthrogryposis multiplex congenita distal (AMCD), also known as X-linked spinal muscular atrophy type 2. Gordon syndrome, also known as distal arthrogryposis type 3. Arthrogryposis multiplex congenita, distal type 2A, also known as Freeman–Sheldon syndrome. Arthrogryposis multiplex congenita, distal type 2B, also known as Sheldon–Hall syndrome. Arthrogryposis multiplex congenita neurogenic type (AMCN). This particular type of AMC has been linked to the AMCN gene on locus 5q35. Arthrogryposis multiplex congenita pulmonary hypoplasia, also with a large number of synonyms. Arthrogryposis multiplex congenita whistling face, also known as Illum syndrome. Arthrogryposis multiplex congenita, distal type 1 (AMCD1). Arthrogryposis multiplex with deafness, inguinal hernias, and early death. This syndrome is suspected to be inherited in an X-linked or autosomal recessive fashion. There were only three reported cases with all three patients dead. Arthrogryposis ophthalmoplegia retinopathy, also known as Oculomelic amyoplasia.

=== Cranial electrotherapy stimulation === A 2014 Cochrane review found insufficient evidence to determine whether or not Cranial electrotherapy stimulation with alternating current is safe and effective for treating depression.

=== Definition === Bacteriology is the study of bacteria. Bacteriology evolved from physicians needing to apply the germ theory to address the concerns relating to disease spreading in hospitals the 19th century. Identification and characterizing of bacteria being associated to diseases led to advances in pathogenic bacteriology. Koch's postulates played a role into identifying the relationships between bacteria and specific diseases. Since then, bacteriology has played a role in successful advances in science such as bacterial vaccines like diphtheria toxoid and tetanus toxoid. Bacteriology can be studied and applied in many sub-fields relating to agriculture, marine biology, water pollution, bacterial genetics, veterinary medicine, biotechnology and others.

=== Brand names === In May 2015, a formulation of paliperidone palmitate was approved by the US Food and Drug Administration under the brand name Invega Trinza. A similar prolonged release suspension was approved in 2016 by the European Medicines Agency originally under the brand name Paliperidone Janssen, later renamed to Trevicta. In September 2021, a newer formulation of paliperidone palmitate, Invega Hafyera, was approved by the US FDA.

=== No development reported === AF-130 – purinergic P2X3 receptor antagonist – migraine [40] B-244 (AOB-101; AOB-102; AOB-103; AOB-201; AOB-202; AOB-203; B244; nitrosomonas eutropha D23) – bacteria replacement – migraine [41] Carabersat (SB-204269) – undefined mechanism of action (anticonvulsant) – migraine [42] CLE-500 – undefined mechanism of action – cluster headache [43] CT-044 analogues - CERSCI Therapeutics – reactive oxygen species (ROS) inhibitor – migraine [44] Cyclobenzaprine extended release (Amrix; Bonelax; EUR-1002) – tricyclic antidepressant (non-selective monoamine reuptake inhibitor and receptor modulator and other actions) – migraine [45] Donepezil (Allydone; Aricept; E-2020; E-2022; Eranz) – acetylcholinesterase inhibitor – migraine [46] Donitriptan mesilate (F-12640) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [47] Estetrol (E4; Donesta) – estrogen (estrogen receptor agonist) – migraine [48] Filorexant (MK-6096) – orexin OX1 and OX2 receptor antagonist – migraine [49] Flunarizine (XEN-007) – calcium channel blocker, non-selective monoamine receptor modulator, other actions – migraine [50] Ibudilast (AV-411; Eyevinal; Ibinal; KC-404; Ketas; MN-166; Pinatos) – phosphodiesterase PDE4 inhibitor – headache [51] IPX-232 – undefined mechanism of action – migraine [52] Ketamine hydrochloride intranasal – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – cluster headache [53] Ondansetron/rizatriptan – oral transmucosal film (rizatriptan/ondansetron; MSRX-202) – combination of ondansetron (serotonin 5-HT3 receptor antagonist and antiemetic) and rizatriptan (triptan) [54] Oxytocin (TI-001; TI-114; TNX-1900; TNX-2900) – oxytocin receptor agonist – headache [55] Piroxicam betadex (β-cyclodextrin piroxicam; Brexecam; Brexidol; Brexin; Brexine; Brexinil; CHF 1194; Cicladol; Cycladol; Flogene; piroxicam β-cyclodextrin) – COX inhibitor/NSAID – migraine, tension-type headache [56] Psilocybin (low-dose psilocybin; BPL-PSILO) – non-selective serotonin receptor agonist and psychedelic hallucinogen – headache [57] Psilocybin (MYCO-001; MYCO-003) – non-selective serotonin receptor agonist and psychedelic hallucinogen – headache [58] Psilocybin (SYNP-101; synthetic psilocybin) – non-selective serotonin receptor agonist and psychedelic hallucinogen – cluster headache, migraine [59] Relutrigine (PRAX-562) – sodium channel blocker – headache [60] Research programme: calcitonin gene-related peptide receptor antagonists - Merck (CGRP receptor antagonists; Imidazoazepanes; MK-2918; MK-8825) – calcitonin gene-related peptide receptor (CGRPR) antagonists [61] Research programme: GPCR modulators - Nxera Pharma – various actions [62] Research programme: migraine and pain therapeutics - NeurAxon – various actions – migraine [63] Research programme: pain and migraine therapy - OptiNose (OPT-1005) – undefined mechanism of action – migraine [64] Rizatriptan intranasal – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [65] Rizatriptan oral film – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [66] Salubrin (PH80; PH-80; ORG-39479) – vomeropherine – migraine [67] [68] Sumatriptan (Imigran Nasal Spray; Imitrex Nasal Spray) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – menstrual migraine [69] Sumatriptan transmucosal (Omexa) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [70] Zucapsaicin (cis-capsaicin; Civamide; Civanex; Dolorac; Neuroderm; Zuacta) – transient receptor potential cation channel subfamily V member 1 (TRPV1) agonist – cluster headache, migraine [71]

Sources: en.wikipedia.org

Supporting material

On 20 September 2014, while speaking to party workers in Multan, Bhutto Zardari said, "I will take back Kashmir, all of it, and I will not leave behind a single inch of it because, like the other provinces, it belongs to Pakistan." The statement was to be the first marking his stance on the Kashmir issue and remarked upon widely in local and international media. On 6 February 2019, Bhutto Zardari met with the Kashmir Council in Washington to express solidarity with the people of Kashmir. During the meeting, he assured the delegation that he would continue to raise his voice against the brutalities of Indian forces against innocent and unarmed Kashmiri people at every available forum both nationally and internationally. He said that loyalty to the cause of Kashmir was in his blood and he would stand with the people of Indian-administered Kashmir in their just struggle for the right to self-determination and freedom from illegal and immoral Indian occupation. On 15 October 2022, after U.S. President Joe Biden referred to Pakistan as "one of the most dangerous nations in the world" and as a carrier of "nuclear weapons without any cohesion" at a Democratic Party fundraiser in California, Bhutto Zardari summoned American diplomat Donald Blome to the Ministry of Foreign Affairs and demanded an explanation as well as called for an official démarche.

Daisho (Dso) is an antimicrobial peptide gene family of the fruit fly Drosophila melanogaster. Two Daisho genes (Dso1, Dso2) are encoded in tandem in the fruit fly genome, one shorter than the other. This pair of genes with different length was named "Daisho" in reference to Daisho Japanese swords, which come in pairs with one shorter than the other. The Daisho genes are regulated by Drosophila Toll-like receptor signalling. Daisho peptides protect flies against filamentous fungi, particularly Fusarium and also Aspergillus. Daisho peptides are part of the Drosophila antifungal effector peptide response, which includes the gene families Bomanin, Drosomycin, Metchnikowin, and Baramicin.

=== Legacy === The RCMP has again become involved in intelligence work, particularly related to counterterrorism, following the bombing of Air India Flight 182 in 1985 and the 9/11 attacks under the Security Offences Act.

Kiana Fitzgerald of Consequence also praised the album's guest performances and lyrical versatility ("The brothers are as contemplative as they are comedic") and complimented the production, highlighting "M.T.B.T.T.F."'s specifically as evoking the golden era of hip-hop. Simon Vozick-Levinson of Rolling Stone gave the album four stars out of five, praising Clipse's "fascinating" emotional growth, but noting that it at times felt like a Pusha T solo album rather than a Clipse album. In an unrated positive review for Variety, Peter A. Berry praised the duo's chemistry, but criticized Williams's contributions, describing the album's production as "somewhat unimaginative" and his choruses on "So Far Ahead" and "By the Grace of God" as "ham-fisted tropes". Jordan Darville of The Fader called the album a "daring move" and a "solid, occasionally brilliant project" with an emotional core around Malice's Christian faith, praising the "grand" instrumentals and Clipse's more introspective lyrics than previous releases, while feeling that the features were more of a mixed bag, specifically criticizing "All Things Considered" for Williams and The-Dream's contributions. Marko Djurdjić of Exclaim! gave the "hostile, paranoid, and often inspiring album" a seven out of ten, praising the overall style of the rapping ("This is fucking rapping, and it is relentless.") and the "beyond impressive" writing while criticizing the flows as repetitive and describing the production on some tracks as "tedious [and] unnecessary".

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan-2 a naturally occurring substance?

No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.

How is melanotan-2 distinguished from afamelanotide?

Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.

Why does the compound appear in tanning-related discussion?

Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.

How is peptide purity usually reported?

Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.

Network